Published in Medicine and Law Weekly, August 3rd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Alexion Pharmaceuticals.
Report 1: Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the European Commission (EC) has approved the use of Soliris(tm) (eculizumab) for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Soliris is the first therapy approved in Europe for the treatment of PNH, a rare, disabling and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis.
Hemolysis can cause one or more...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly